Insider · CIK 0001799365
Sian Bigora
Files at PCSA (Processa Pharmaceuticals, Inc.). First filing Apr 1, 2026, latest May 19, 2026.
In brief
Sian Bigora files SEC Form 4 as officer at PCSA (Processa Pharmaceuticals, Inc.). Since Apr 1, 2026, Sian Bigora has reported 4 open-market buys worth $21k and 0 open-market sells worth $0, the latest filed on May 19, 2026.
A track record needs three past buys with six months of prices behind them; Sian Bigora has 1, so none is measured yet.
The newest scored trade: bought $5,341 of PCSA on Apr 30, 2026, filed May 19, 2026, scored 49 (moderate). In the last 12 months: 4 buys worth $21k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PCSA: Processa Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 49Moderate | Processa Pharmaceuticals, Inc. | $5,341 1,971 shares | +36% | +46% from low-77% from high | |
| 49Moderate | Processa Pharmaceuticals, Inc. | $5,342 1,986 shares | +36% | +46% from low-77% from high | |
| 49Moderate | Processa Pharmaceuticals, Inc. | $5,343 1,799 shares | +48% | +60% from low-75% from high | |
| 48Moderate | Processa Pharmaceuticals, Inc. | $5,341 2,107 shares | +131% | +36% from low-79% from high |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,971 | $2.71 | $5,341 | 7,481 | May 19, 2026 |
| Apr 30, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,986 | $2.69 | $5,342 | 7,496 | May 1, 2026 |
| Apr 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,799 | $2.97 | $5,343 | 5,510 | Apr 17, 2026 |
| Mar 31, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +2,107 | $2.54 | $5,341 | 3,711 | Apr 1, 2026 |
| Jan 1, 2026 | PCSA Processa Pharmaceuticals, Inc. | MOption exercise Common Stock | +249 | $0.00 | $0 | 1,604 | Feb 4, 2026 |
| Jan 1, 2026 | PCSA Processa Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -249 | $0.00 | $0 | 0 | Feb 4, 2026 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +96,000 | $0.00 | $0 | 96,000 | Oct 3, 2025 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +288,000 | $0.00 | $0 | 288,000 | Oct 3, 2025 |
| Jul 24, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +1,659,185 | $0.00 | $0 | 1,672,087 | Jul 28, 2025 |
| Apr 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | MOption exercise Common Stock | +15,059 | - | - | 36,937 | Apr 11, 2025 |
| Apr 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | FTax withholding Common Stock | -3,311 | $0.41 | $1,364 | 33,626 | Apr 11, 2025 |
Questions about Sian Bigora
Answered from the filings on this page, as of the latest one.
Is Sian Bigora buying or selling?
In the last 12 months Sian Bigora reported 4 open-market buys worth $21k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $5,341 of PCSA on Apr 30, 2026. Grants, option exercises and tax withholding are not counted.
How did Sian Bigora's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sian Bigora has 1.
Where does Sian Bigora file Form 4?
Sian Bigora has filed Form 4 at PCSA (Processa Pharmaceuticals, Inc.) as Chief Development Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.